Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 6/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7835046 | 0.78 | PARP1 (0.39) | PARP1ALDH1A1KDM4ELMNACYP1A2 | |
| SCHEMBL4341520 | 0.77 | ALDH1A1 (0.47) | PARP1ALDH1A1KDM4ELMNACYP1A2 | |
| SCHEMBL15716637 | 0.74 | CYP2A6 (0.42) | PARP1ALDH1A1KDM4ELMNACYP1A2 | |
| SCHEMBL7058856 | 0.73 | MCL1 (0.38) | PARP1ALDH1A1KDM4ELMNACYP1A2 | |
| SCHEMBL22323693 | 0.73 | MGLL (0.41) | PARP1ALDH1A1KDM4ELMNACYP1A2 | |
| SCHEMBL5849531 | 0.73 | TMIGD3 (0.51) | PARP1ALDH1A1KDM4ELMNACYP1A2 | |
| SCHEMBL15728254 | 0.73 | PARP1 (0.35) | PARP1ALDH1A1KDM4ELMNACYP1A2 | |
| SCHEMBL20586642 | 0.73 | CYP2A6 (0.41) | PARP1ALDH1A1KDM4ELMNACYP1A2 | |
| SCHEMBL12219884 | 0.73 | PARP1 (0.35) | PARP1ALDH1A1KDM4ELMNACYP1A2 | |
| SCHEMBL10647302 | 0.72 | CA2 (0.53) | PARP1ALDH1A1KDM4ELMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12528825-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12509460-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250276978-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2025-09-04 | — | — | US | disclosed |
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. | 2025-05-08 | — | — | US | disclosed |
| US-12227515-B2 | In-flow photooxygenation of aminothienopyridinones generates novel PTP4A3 phosphatase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-02-18 | — | — | US | disclosed |
| US-12202839-B2 | In-flow photooxygenation of aminothienopyridinones generates PTP4A3 phosphatase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-01-21 | — | — | US | disclosed |
| EP-4433059-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | Erasca, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| EP-2920183-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | Glaxosmithkline LLC (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014078257-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078257-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-05-22 | — | — | WO | disclosed |
| US-7943639-B2 | Such as 6-benzenesulfonyl-4-piperazin-1-yl-quinoline hydrochloride; for treatment of central nervous system and/or 5- HT6 receptor related disorders; for weight gain/loss | PROXIMAGEN LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-7943639-B2 | Such as 6-benzenesulfonyl-4-piperazin-1-yl-quinoline hydrochloride; for treatment of central nervous system and/or 5- HT6 receptor related disorders; for weight gain/loss | PROXIMAGEN LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| EP-1897881-A2 | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders | Biovitrum AB (publ) (SE) | 2008-03-12 | — | — | EP | disclosed |
| EP-1556053-A4 | ANTIINFLAMMATION AGENTS | AMGEN INC (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1556053-A1 | ANTIINFLAMMATION AGENTS | Amgen Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004041285-A1 | ANTIINFLAMMATION AGENTS | AMGEN INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040024210-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | PARP1 869/4885ALDH1A1 3129/4885KDM4E 1266/4885 |
| US-20250276978-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | BET1, BRD4, BRD3 | PARP1 408/4885ALDH1A1 4239/4885KDM4E 555/4885 |
| US-12509460-B2 | Methods and compositions for modulating splicing | SF3B1, RTCB, RBM17 | PARP1 2329/4885ALDH1A1 3032/4885KDM4E 2036/4885 |
| US-20040024210-A1 | New compounds | SULT1E1, SULT2A1, SULT1A1 | PARP1 4152/4885ALDH1A1 705/4885KDM4E 2527/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | PARP1 4713/4885ALDH1A1 700/4885KDM4E 684/4885 |
| US-12202839-B2 | In-flow photooxygenation of aminothienopyridinones generates PTP4A3 phosphatase inhibitors | PTP4A3, PTPRO, PTPRC | PARP1 1151/4885ALDH1A1 1667/4885KDM4E 176/4885 |
| US-12528825-B2 | Compounds and uses thereof | BRD9, BRD8, BRIX1 | PARP1 2033/4885ALDH1A1 4477/4885KDM4E 574/4885 |
| US-12227515-B2 | In-flow photooxygenation of aminothienopyridinones generates novel PTP4A3 phosphatase inhibitors | PTP4A3, PTPRC, PTPRF | PARP1 1313/4885ALDH1A1 1620/4885KDM4E 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.